Drug Profile
Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB Therapeutics
Alternative Names: Glutathione-pegylated liposomal therapeutics - Sihuan/to-BBBLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Sihuan Pharmaceutical Holdings Group; to-BBB technologies
- Developer BBB Therapeutics; Sihuan Pharmaceutical Holdings Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in CNS-disorders in China (Parenteral, Liposomal)
- 28 Jan 2018 No recent reports of development identified for research development in CNS-disorders in Netherlands (Parenteral, Liposomal)
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics